Abstracts tagged "joint destruction"

Abstract Number: 125 • 2014 ACR/ARHP Annual Meeting
PD Signal Detected By Ultrasonography Relates to Joint Destruction in Rheumatoid Arthritis Under Biologics Therapy in Real World
Maasa Hama¹, Yumiko Sugiyama¹, Naomi Tsuchida¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Reikou Kamiyama¹, Kaoru Minegishi-Takase¹, Ryusuke Yoshimi¹, Yohei Kirino², Mitsuhiro Takeno³, Atsuhisa Ueda¹ and Yoshiaki Ishigatsubo¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
Background/Purpose: Biologic DMARD (biologics) therapy for rheumatoid arthritis (RA) strongly suppresses joint destruction regardless of its efficacy for disease activity. On the contrary power Doppler…
Abstract Number: 119 • 2014 ACR/ARHP Annual Meeting
Sonographic Evaluation of the Fifth Metatarsophalangeal Joint Erosion in Rheumatoid Arthritis
Nevsun Inanc¹, Gulsen Ozen¹, Sibel Z. Aydin², Esen Kasapoglu Gunal³ and Haner Direskeneli¹, ¹Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Department of Rheumatology, Koc University Faculty of Medicine, Istanbul, Turkey, ³Department of Rheumatology, Goztepe Medeniyet University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Joint erosions in RA correlate with structural damage progression and functional capacity. Therefore, detection and the follow-up of erosions are of paramount importance for…
Abstract Number: 2505 • 2014 ACR/ARHP Annual Meeting
Long-Term Treatment with Tocilizumab (TCZ) Strongly Suppresses Joint Destruction in Biologic-naïve Patients with Rheumatoid Arthritis (RA) Regardless of Inflammation Status
Akira Sagawa, Sagawa Akira Rheumatology Clinic, Sapporo,060-0001, Japan
Background/Purpose: It is still difficult to completely prevent the progression of joint destruction with any of the currently available biologics. It has been reported that…
Abstract Number: 1199 • 2014 ACR/ARHP Annual Meeting
Alarmins S100A8/S100A9 Aggravate Osteophyte Formation in Experimental Osteoarthritis and Predict Osteophyte Progression in EARLY Human Osteoarthritis in the Dutch Check Cohort
Rik Schelbergen¹, Wouter de Munter², Martijn van den Bosch³, Floris Lafeber⁴, Annet Sloetjes³, Thomas Vogl⁵, Johannes Roth⁵, Peter M. van der Kraan⁶, Arjen B. Blom³, Wim B van den Berg³ and Peter L. van Lent³, ¹Radboud university medical center, Nijmegen, Netherlands, ²Experimental rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁶Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose The main pathological feature of osteoarthritis (OA) is degradation of the articular cartilage. Other important hallmarks include subclinical inflammation of the synovium and ectopic…
Abstract Number: 1123 • 2014 ACR/ARHP Annual Meeting
Impact of Genes Modulating Serum Low-Density Lipoprotein Cholesterol Levels on Progression of Joint Destruction in Japanese Patients with Rheumatoid Arthritis
Shinji Yoshida¹, Katsunori Ikari¹, Koichiro Yano¹, Yoshiaki Toyama², Atsuo Taniguchi³, Hisashi Yamanaka¹ and Shigeki Momohara³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Patients with rheumatoid arthritis (RA) have a higher prevalence of dyslipidemia than healthy individuals. Since RA is a chronic inflammatory disease, an inflammatory response…
Abstract Number: 174 • 2013 ACR/ARHP Annual Meeting
Genetic Association On Disease Severity In Rheumatoid Arthritis: A Validation Study In Japanese Patients
Shinji Yoshida¹, Katsunori Ikari¹, Koichiro Yano¹, Yoshiaki Toyama², Atsuo Taniguchi³, Hisashi Yamanaka¹ and Shigeki Momohara³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: The disease severity of rheumatoid arthritis (RA) is objectively measured by radiographic joint destruction, which is reflective of the cumulative burden of inflammation. Recently,…
Abstract Number: 1726 • 2013 ACR/ARHP Annual Meeting
Survivin Inhibition Disturbs Bcl-6 and Blimp-1 Control Of Lymphocyte Maturation and Alleviates Antigen-Induced Arthritis
Mattias Svensson¹, Karin Andersson¹, Malin Erlandsson¹, Ing-Marie Jonsson² and Maria Bokarewa¹, ¹Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Göteborgs University, Göteborg, Sweden
Background/Purpose: Survivin is a proto-oncogene known to regulate cell division and apoptosis. In patients with rheumatoid arthritis, survivin has emerged as an independent predictor of…
Abstract Number: 1457 • 2013 ACR/ARHP Annual Meeting
Inhibitory Effect Of Abatacept On Joint Damage In Rheumatoid Arthritis Patients With Or Without Concomitant Methotrexate: A Retrospective Multicenter Analysis Of 12 Months Of Abatacept Treatment In Routine Clinical Practice
Isao Matsushita¹, Hiraku Motomura¹, Eiko Seki¹ and Tomoatsu Kimura², ¹Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan, ²Department of rthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: Abatacept is approved for use with or without methotrexate (MTX). The purpose of this study was to clarify the inhibitory effect of abatacept on…
Abstract Number: 1453 • 2013 ACR/ARHP Annual Meeting
Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA^® DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors
Shintaro Hirata¹, Wanying Li², Nadine A. Defranoux², Rebecca Bolce², Eric H. Sasso², Satoshi Kubo¹, Shunsuke Fukuyo¹, Kentaro Hanami³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA, ³The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A novel multi-biomarker disease activity (MBDA) score that is based on the serum concentrations of 12 biomarkers has been shown to correlate with clinical…
Abstract Number: 79 • 2013 ACR/ARHP Annual Meeting
Synovial Activation In Experimental OA Drives Immuno suppressive Effects Of Adipose-derived Stem Cells After Local Administration and Protects Against Chondrogenesis In Ligaments
Peter L.E.M. van Lent¹, Rik Schelbergen¹, Menno C. ter Huurne², Arjen B. Blom¹, Johannes Roth³, Thomas Vogl⁴, Christian Jorgensen⁵ and Wim B. van den Berg⁶, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁴Institute of Immunology, University of Muenster, Muenster, Germany, ⁵Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, ⁶Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: A substantial subpopulation of patients with early osteoarthritis (OA) show a thickened synovial lining layer comprising macrophages expressing an activated phenotype (reflected by production of…
Abstract Number: 895 • 2012 ACR/ARHP Annual Meeting
Transcriptomics of Synovial Tissue of Early Human (CHECK) and Experimental OA Identify Pathways Associated with Cartilage Damage
Arjen B. Blom¹, Peter L.E.M. van Lent², Martijn H. van den Bosch¹, Hans Cats³, Peter M. van der Kraan¹ and Wim B. van den Berg⁴, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology, Rheumatology Centre Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Many osteoarthritis (OA) patients show synovial inflammation, even relatively early during the disease. Mechanisms through which synovial activation contributes to the joint pathology that…
Abstract Number: 809 • 2012 ACR/ARHP Annual Meeting
Ultrasonography Predicts Achievement of Deeper Remission After DAS28-Based Clinical Remission of Rheumatoid Arthritis
Ryusuke Yoshimi¹, Maasa Hama¹, Daiga Kishimoto¹, Reikou Watanabe¹, Takeaki Uehara², Yukiko Asami¹, Atsushi Ihata¹, Atsuhisa Ueda¹, Mitsuhiro Takeno¹ and Yoshiaki Ishigatsubo¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatology, Chigasaki Municipal Hospital, Chigasaki, Japan
Background/Purpose: Although clinical remission is an agreeable goal of treatment in rheumatoid arthritis (RA), the definition is still controversial. Indeed, progressive structural damage is often…
Abstract Number: 733 • 2012 ACR/ARHP Annual Meeting
Intra-Articular Injection of Adipose-Derived Stem Cells Inhibits Activation of the Synovium and Protects Against Cartilage Damage and Enthesophyte Formation in Murine Experimental Osteoarthritis
Peter L.E.M. van Lent¹, Menno C. ter Huurne², Arjen B. Blom³, Rik Schelbergen³, Louis Casteilla⁴, Thomas Vogl⁵, Johannes Roth⁵, Roxane Blattes⁴, Christian Jorgensen⁶ and Wim B. van den Berg⁷, ¹Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴STROMALab UPS/CNRS UMR5273, INSERM U1031, Toulouse, France, ⁵Institute of Immunology, University of Muenster, Munster, Germany, ⁶Department of therapy & Immuno-Rhumatology, Hospital Lapeyronie, Montpellier, France, ⁷Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: OA lesions are treated with mesenchymal stem cells aiming to enhance tissue repair by transformation to eg. chondrocytes. Recently it has been shown that…
Abstract Number: 370 • 2012 ACR/ARHP Annual Meeting
Characteristic of the Japanese Patients with Rheumatoid Arthritis (RA) of Rapid Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (the 1st report of Apple Survey)
Akitomo Okada¹, Atsushi Kawakami², Takaaki Fukuda³, Toshihiko Hidaka⁴, Tomonori Ishii⁵, Yukitaka Ueki⁶, Takao Kodera⁷, Munetoshi Nakashima⁸, Yuichi Takahashi⁹, Seiyo Honda¹⁰, Yoshiro Horai², Tomohiro Koga¹, Ryu Watanabe¹¹, Hiroshi Okuno¹² and Katsumi Eguchi¹³, ¹Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, ⁴Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁶Sasebo Chuo Hospital, Sasebo, Japan, ⁷Tohoku Kosei Nenkin Hospital, Sendai, Japan, ⁸Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁹Yu Family Clinic, Sendai, Japan, ¹⁰Kurume University School of Medicene, Kurume, Japan, ¹¹Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, ¹²Tohoku University Hospital, Sendai, Japan, ¹³Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: There has been few epidemiological report of longitudinal radiographic progression in rheumatoid arthritis (RA) patients captured in daily practice. In 20 related-centers of the…
Abstract Number: 371 • 2012 ACR/ARHP Annual Meeting
Treat-to-Target Strategy Aiming At Achievement of Structural and Functional Remission in Patients with Active Elderly-Onset Rheumatoid Arthritis
Takahiko Sugihara¹, Tatsuro Ishizaki², Tadashi Hosoya¹, Shoko Iga¹, Waka Yokoyama¹, Fumio Hirano¹, Nobuyuki Miyasaka³ and Masayoshi Harigai⁴, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Human Care Research Team, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, ³Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Treat-to-target is the consensus treatment strategy for patients with rheumatoid arthritis (RA), but supporting evidence for treat-to-target strategy in elderly RA patients in clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.